KalVista Pharmaceuticals (NASDAQ:KALV) CFO Sells $39,875.42 in Stock

Posted by Brenda Bartman on May 29th, 2026

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV – Get Free Report) CFO Brian Piekos sold 1,489 shares of the firm’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $26.78, for a total transaction of $39,875.42. Following the sale, the chief financial officer directly owned 21,661 shares in the company, valued at $580,081.58. The trade was a 6.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Brian Piekos also recently made the following trade(s):

On Friday, April 17th, Brian Piekos sold 1,862 shares of KalVista Pharmaceuticals stock. The stock was sold at an average price of $20.22, for a total transaction of $37,649.64.

KalVista Pharmaceuticals Price Performance

Shares of NASDAQ KALV opened at $26.77 on Friday. The stock has a market capitalization of $1.43 billion, a price-to-earnings ratio of -7.74 and a beta of -0.12. KalVista Pharmaceuticals, Inc. has a 12 month low of $9.83 and a 12 month high of $26.85. The firm’s 50 day simple moving average is $22.14 and its 200-day simple moving average is $17.76. The company has a debt-to-equity ratio of 8.18, a current ratio of 5.17 and a quick ratio of 5.10.

KalVista Pharmaceuticals (NASDAQ:KALV – Get Free Report) last issued its quarterly earnings data on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) EPS for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The firm had revenue of $40.86 million for the quarter, compared to analyst estimates of $39.03 million. Analysts expect that KalVista Pharmaceuticals, Inc. will post -0.96 EPS for the current year.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Tudor Investment Corp ET AL purchased a new stake in KalVista Pharmaceuticals during the 3rd quarter worth approximately $24,360,000. Jefferies Financial Group Inc. purchased a new stake in KalVista Pharmaceuticals during the 3rd quarter worth approximately $3,494,000. Blue Owl Capital Holdings LP purchased a new stake in KalVista Pharmaceuticals during the 3rd quarter worth approximately $1,522,000. Hennion & Walsh Asset Management Inc. increased its stake in KalVista Pharmaceuticals by 93.6% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 341,819 shares of the specialty pharmaceutical company’s stock worth $5,520,000 after buying an additional 165,236 shares in the last quarter. Finally, Skandinaviska Enskilda Banken AB publ increased its stake in KalVista Pharmaceuticals by 391.9% during the 3rd quarter. Skandinaviska Enskilda Banken AB publ now owns 200,991 shares of the specialty pharmaceutical company’s stock worth $2,449,000 after buying an additional 160,128 shares in the last quarter.

Wall Street Analyst Weigh In

KALV has been the topic of a number of analyst reports. Needham & Company LLC cut KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, April 30th. Wall Street Zen cut KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, April 21st. HC Wainwright cut KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their target price for the company from $37.00 to $27.00 in a research report on Friday, May 1st. Leerink Partners cut KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, April 29th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 21st. Three analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, KalVista Pharmaceuticals currently has an average rating of “Hold” and an average target price of $30.60.

Check Out Our Latest Research Report on KalVista Pharmaceuticals

KalVista Pharmaceuticals Company Profile

(Get Free Report)

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.